Outlook Therapeutics, Inc. (OTLK) Deep Dive Video

Outlook Therapeutics is a high-risk, high-upside FDA appeal winner whose value hinges on whether LYTENAVA can turn compounding law into a commercial moat before dilution overwhelms shareholders.